Cargando…

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has form...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fizazi, Karim, Albiges, Laurence, Loriot, Yohann, Massard, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2015
Materias:	Drug Profile
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673554/ https://www.ncbi.nlm.nih.gov/pubmed/26313416 http://dx.doi.org/10.1586/14737140.2015.1081566

Ejemplares similares

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
por: Moilanen, Anu-Maarit, et al.
Publicado: (2015)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic
por: Patrikidou, Anna, et al.
Publicado: (2018)

Spinosad: An effective and safe pediculicide
por: Aditya, Suruchi, et al.
Publicado: (2012)

Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013)

Antioxidants in dermatology
por: Pai, Varadraj V., et al.
Publicado: (2014)

Ingenol mebutate: A novel topical drug for actinic keratosis
por: Aditya, Suruchi, et al.
Publicado: (2013)

Fumaric acid esters in dermatology
por: Wollina, Uwe
Publicado: (2011)

Finasteride and sexual side effects
por: Mysore, Venkataram
Publicado: (2012)

Vitamin C in dermatology
por: Telang, Pumori Saokar
Publicado: (2013)

Aspirin in dermatology: Revisited
por: Bubna, Aditya Kumar
Publicado: (2015)

PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
por: Duffy, Danielle, et al.
Publicado: (2014)

Pentoxifylline and its applications in dermatology
por: Hassan, Iffat, et al.
Publicado: (2014)

Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)
por: Mitchell, William M
Publicado: (2016)

Vitamin E in dermatology
por: Keen, Mohammad Abid, et al.
Publicado: (2016)

Bimatoprost in Dermatology
por: Jha, Abhijeet K., et al.
Publicado: (2018)

Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal
por: Sonthalia, Sidharth, et al.
Publicado: (2019)

Hydroxychloroquine in Dermatology and Beyond: Recent Update
por: Sardana, Kabir, et al.
Publicado: (2020)

Amphotericin-B in Dermatology
por: Agarwal, Akash, et al.
Publicado: (2022)

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
por: Lindsay, C. R., et al.
Publicado: (2016)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

ODM2CDA and CDA2ODM: Tools to convert documentation forms between EDC and EHR systems
por: Dugas, Martin
Publicado: (2015)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Niacin Extended Release (ER)/Simvastatin (Simcor®): A Guide to its Use in Lipid Regulation
por: Lyseng-Williamson, Katherine A.
Publicado: (2012)

Immune Globulin Subcutaneous (Human) 20%: In Primary Immunodeficiency Disorders
por: McCormack, Paul L.
Publicado: (2012)

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study
por: Massard, Christophe, et al.
Publicado: (2016)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
por: Chung, Doo Yong, et al.
Publicado: (2021)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
por: Bono, Petri, et al.
Publicado: (2020)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gro2i1jddauh5jc8g01dvi9fnd